A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma

Leuk Lymphoma. 2014 Jan;55(1):201-3. doi: 10.3109/10428194.2013.794268. Epub 2013 Jun 5.

Authors

Amrita Y Krishnan¹, Shirong Wang, Joycelynne M Palmer, Ni-Chun Tsai, Sandra H Thomas, Myo Htut, Len Farol, Stephen J Forman

Affiliation

¹ Department of Hematology & Hematopoietic Cell Transplantation.

PMID: 23573824
DOI: 10.3109/10428194.2013.794268

No abstract available

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Administration, Intravenous
Adult
Aged
Benzylamines
Cyclams
Cyclophosphamide / administration & dosage*
Female
Granulocyte Colony-Stimulating Factor / administration & dosage
Hematopoietic Stem Cell Mobilization*
Heterocyclic Compounds / administration & dosage*
Humans
Male
Middle Aged
Multiple Myeloma / therapy*
Myeloablative Agonists / administration & dosage*
Treatment Outcome

Substances

Benzylamines
Cyclams
Heterocyclic Compounds
Myeloablative Agonists
Granulocyte Colony-Stimulating Factor
Cyclophosphamide
plerixafor